|
INN ▲
|
ATC Code ▲
|
Country ▲
|
Classification ▲
|
Last update ▼
|
MA Number ▲
|
Registration date ▲
|
Status ▲
|
|
INEBILIZUMAB |
L04AG10 |
FR
|
I
|
27-02-2023 |
EMEA/H/C/005818 |
25-04-2022 |
VALID
|
|
LASMIDITAN |
N02CC08 |
FR
|
I
|
27-02-2023 |
EMEA/H/C/005332 |
17-08-2022 |
VALID
|
|
LENACAPAVIR |
J05AX31 |
FR
|
I
|
27-02-2023 |
EMEA/H/C/005638 |
17-08-2022 |
VALID
|
|
LINZAGOLIX |
H01CC04 |
FR
|
I
|
27-02-2023 |
EMEA/H/C/005442 |
14-06-2022 |
VALID
|
|
LONAFARNIB |
A16AX20 |
FR
|
I
|
27-02-2023 |
EMEA/H/C/005271 |
18-07-2022 |
VALID
|
|
MELPHALAN FLUFENAMIDE |
L01AA10 |
FR
|
I
|
27-02-2023 |
EMEA/H/C/005681 |
17-08-2022 |
VALID
|
|
METHOCARBAMOL |
M03BA03 |
FR
|
II
|
27-02-2023 |
|
|
VALID
|
|
NIVOLUMAB AND RELATLIMAB |
L01FY02 |
FR
|
I
|
27-02-2023 |
EMEA/H/C/005481 |
15-09-2022 |
VALID
|
|
OLIPUDASE ALFA |
A16AB25 |
FR
|
I
|
27-02-2023 |
EMEA/H/C/004850 |
24-06-2022 |
VALID
|
|
P-TOLUENEDIAMINE |
V04CL |
FR
|
I
|
27-02-2023 |
None |
|
VALID
|
|
RELUGOLIX |
L02BX04 |
FR
|
I
|
27-02-2023 |
EMEA/H/C/005353 |
29-04-2022 |
VALID
|
|
RIMEGEPANT |
N02CD06 |
FR
|
I
|
27-02-2023 |
EMEA/H/C/005725 |
25-04-2022 |
VALID
|
|
TEBENTAFUSP |
L01XX75 |
FR
|
I
|
27-02-2023 |
EMEA/H/C/004929 |
01-04-2022 |
VALID
|
|
TEZEPELUMAB |
R03DX11 |
FR
|
I
|
27-02-2023 |
EMEA/H/C/005588 |
19-09-2022 |
VALID
|
|
TIXAGEVIMAB AND CILGAVIMAB |
J06BD03 |
FR
|
I
|
27-02-2023 |
EMEA/H/C/005788 |
25-03-2022 |
VALID
|
|
VOCLOSPORIN |
L04AD03 |
FR
|
I
|
27-02-2023 |
EMEA/H/C/005256 |
15-09-2022 |
VALID
|
|
VUTRISIRAN |
N07XX18 |
FR
|
I
|
27-02-2023 |
EMEA/H/C/005852 |
15-09-2022 |
VALID
|
|
AZELASTINE |
S01GX07 |
FR
|
I
|
23-02-2023 |
|
|
VALID
|
|
EMEDASTINE |
S01GX06 |
FR
|
I
|
23-02-2023 |
|
|
VALID
|
|
EPINASTINE |
S01GX10 |
FR
|
I
|
23-02-2023 |
|
|
VALID
|
|
LEVOCABASTINE |
S01GX02 |
FR
|
II + Exemption
|
23-02-2023 |
|
|
VALID
|
|
LODOXAMIDE |
S01GX05 |
FR
|
Not authorised
|
23-02-2023 |
|
|
VALID
|
|
NEDOCROMIL |
S01GX04 |
FR
|
Not authorised
|
23-02-2023 |
|
|
VALID
|
|
OLOPATADINE |
S01GX09 |
FR
|
I
|
23-02-2023 |
|
|
VALID
|
|
CROMOGLICIC ACID |
S01GX01 |
FR
|
Not subject to prescription
|
21-02-2023 |
FR/H/0234/001/II/006 |
06-12-2006 |
VALID
|
|
PHENYLEPHRINE, COMBINATIONS |
S01GA55 |
FR
|
Not authorised
|
20-02-2023 |
|
|
VALID
|
|
OXYMETAZOLINE |
S01GA04 |
FR
|
Not authorised
|
25-01-2023 |
|
|
VALID
|
|
TETRYZOLINE |
S01GA02 |
FR
|
Not authorised
|
25-01-2023 |
|
|
VALID
|
|
SPIRAMYCIN |
J01FA02 |
FR
|
Not authorised
|
21-11-2022 |
|
|
VALID
|
|
NALOXONE |
V03AB15 |
FR
|
I + Exemption
|
12-07-2022 |
|
|
VALID
|
|
LOMEFLOXACIN |
S01AE04 |
FR
|
Not authorised
|
11-07-2022 |
|
|
VALID
|
|
CIPROFLOXACIN |
J01MA02 |
FR
|
I
|
29-06-2022 |
FR/H/0416/002/ |
22-07-2014 |
VALID
|
|
FERROUS GLUCONATE |
B03AA03 |
FR
|
Not authorised
|
24-06-2022 |
|
|
VALID
|
|
ATAZANAVIR |
J05AE08 |
FR
|
I
|
07-06-2022 |
|
|
VALID
|
|
ABROCITINIB |
D11AH08 |
FR
|
I
|
25-04-2022 |
EMEA/H/C/005452 |
09-12-2021 |
VALID
|
|
ALPELISIB |
L01EM03 |
FR
|
I
|
25-04-2022 |
|
|
VALID
|
|
AMIVANTAMAB |
L01FX18 |
FR
|
I
|
25-04-2022 |
EMEA/H/C/005454 |
09-12-2021 |
VALID
|
|
ANIFROLUMAB |
L04AG11 |
FR
|
I
|
25-04-2022 |
EMEA/H/C/004975 |
14-02-2022 |
VALID
|
|
ARTESUNATE |
P01BE03 |
FR
|
I
|
25-04-2022 |
EMEA/H/C/005550 |
22-11-2021 |
VALID
|
|
AVACOPAN |
L04AJ05 |
FR
|
I
|
25-04-2022 |
EMEA/H/C/005523 |
11-01-2022 |
VALID
|
|
CASIRIVIMAB AND IMDEVIMAB |
J06BD07 |
FR
|
I
|
25-04-2022 |
EMEA/H/C/005814 |
12-11-2021 |
VALID
|
|
EPTINEZUMAB |
N02CD05 |
FR
|
I
|
25-04-2022 |
EMEA/H/C/005287 |
24-01-2022 |
VALID
|
|
FINERENONE |
C03DA05 |
FR
|
I
|
25-04-2022 |
EMEA/H/C/005200 |
16-02-2022 |
VALID
|
|
LONAPEGSOMATROPIN |
H01AC09 |
FR
|
I
|
25-04-2022 |
EMEA/H/C/005367 |
11-01-2022 |
VALID
|
|
PEGCETACOPLAN |
L04AJ03 |
FR
|
I
|
25-04-2022 |
EMEA/H/C/005553 |
13-12-2021 |
VALID
|
|
PNEUMOCOCCUS, PURIFIED POLYSACCHARIDES ANTIGEN CONJUGATED |
J07AL02 |
FR
|
I
|
25-04-2022 |
EMEA/H/C/005451 |
14-02-2022 |
VALID
|
|
PRALSETINIB |
L01EX23 |
FR
|
I
|
25-04-2022 |
EMEA/H/C/005413 |
18-11-2021 |
VALID
|
|
REGDANVIMAB |
J06BD06 |
FR
|
I
|
25-04-2022 |
EMEA/H/C/005854 |
12-11-2021 |
VALID
|
|
RIPRETINIB |
L01EX19 |
FR
|
I
|
25-04-2022 |
EMEA/H/C/005614 |
18-11-2021 |
VALID
|
|
SACITUZUMAB GOVITECAN |
L01FX17 |
FR
|
I
|
25-04-2022 |
EMEA/H/C/005182 |
22-11-2021 |
VALID
|
